Pfizer Halts Testing of Two Drug Candidates

Drug Industry Daily
A A
Pfizer is terminating development of two late-stage drug products, one for fibromyalgia and the other for generalized anxiety disorder, because neither compound would give patients a meaningful benefit compared with current treatments.

To View This Article:

Login

Subscribe To Drug Industry Daily